A Phase 1/2 interventional study of ALN-CFB and Placebo in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia, sponsored by Regeneron Pharmaceuticals. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2026, is the only one in phase 1/2, and was the 10th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Italy and 4 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Colombia and 18 more countries
Ages 18+
By country, each count listing its studies:
Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5
First in 2019; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 24 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 24 across the 9 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called ALN-CFB. The study is focused on people with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are currently taking a complement component C5 inhibitor ("C5-inhibitor") and continue to have anemia (low red blood cell count).
The aim of the study is to see how tolerable ALN-CFB is compared to placebo. A placebo looks like the study drug but does not contain any drug.
The study is looking at several other research questions, including:
The protocol will be amended to describe Part B of the study after Part A data have been analyzed.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ALN-CFB
Drug: Placebo
Administered as defined in the protocol
Administered as defined in the protocol
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Through 365 Days
Severity of TEAEs
Time frame: Through 365 Days
Concentrations of combined ALN-CFB and major metabolites in plasma
Time frame: Through 365 Days
Concentrations of combined ALN-CFB and major metabolites in urine
Time frame: Through 24 Hours following ALN-CFB administration
Absolute change from baseline in CFB concentration
Time frame: Baseline, Through 365 Days
Percentage change from baseline in CFB concentration
Time frame: Baseline, Through 365 Days
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Nov 2029, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.